только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-1687
  2. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013;33(1):27-45
  3. Демьянова КА. Роль изменений комплемента в развитии поражения почек у больных с микроангиопатическими синдромами: дис. канд. мед. наук: 14.01.29. - М., 2018. - 152 с
  4. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangoipathies: unreveling Ariadneʾs thread into labyrinth of complement therapeutics. Front Immunol 2019;10:337. doi: 10.3389/fimmu.2019.00337
  5. Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr 2014;61(1):335-356
  6. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010;21:2180-2187
  7. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8(4):554-562
  8. Yoshida Y, Kato H, IkedaY, Nangaku M. Pathogenesis of atypical haemolytic uraemic syndrome. J Atheroscler Thromb 2019;26:99-110. doi: 10.5551/jat.RV17026
  9. Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40:422-430. doi: 10.1055/s-0034-1375296
  10. Jozsi M, Licht C, Strobel S et al. Factor F autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-1514
  11. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8(11):622-633
  12. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013;24(6):496-502. doi: 10.1016/j.ejim.2013.05.009
  13. Riedl M, Fakhouri F, Le Quintrec M et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014;40:444-464
  14. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet 2017;390:681-696. doi: 10.1016/S0140-6736(17)30062-4
  15. Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014;28(2):67-74
  16. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. doi: 10.1186/1750-1172-6-60
  17. Yan K, Desai K, Gullapalli L et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clinical Epidemiology 2020;12:295-305
  18. Besbas N, Karpman D, Landau, Daniel LC. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, and related disorders. Europian Paediatric Research Group for HUS. Kidney International 2006;70:423-431
  19. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
  20. Moake J. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Best Practice&Research Clinical Haematology 2009;22:567-576
  21. Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusion from a “Kidney Disease: improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2017;91(3):539-551. doi: 10.1016/j.kint.2016.10.005
  22. Kato H, Nangaku M, Okada H, Kagami S. Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology 2017;22(1). doi: 10.1007/ s10157-017-1524-4
  23. Le Clech A, Simon-Tillaux N, Provot F et al. Atypical and secondary hemolytic uremic syndrome have a distinct presentation and no common genetic risk factors. Kidney Int 2019;95:1443-1452. doi: 10.1016/j.kint2019.01.023
  24. Praga M, Rodriguez de Cordoba S. Secondary atypical hemolytic uremic syndrome in the era of complement blockade. Kidney Int 2019;95:1298-1300. doi: 10.1016/j/kint2019.01.043
  25. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the кidney. Clin J Am Soc Nephrol 2018;13:300-317. doi: 10.2215/CJN.00620117
  26. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clinical Kidney Journal 2019;12(3):333-337. doi: 10.1093/ckj/sfz040
  27. Sallée M, Ismail K, Fakhouri F et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 2013;14(3):1-6
  28. Hofer J, Rosales A, Fisher C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Pediatric Nephrol 2014;2:1-16
  29. Swisher KK, Doan JT, Vesely SK et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007;92:936-943
  30. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014;10(3):174-180
  31. Sallee M, Daniel L, Piercecchi M et al. Myocardial infarction is a complication of factor H associated atypical HUS. Nephrol Dial Transplant 2010;25:2028-2032
  32. Jokiranta S. HUS and atypical HUS. Blood 2017;21(129):2847-2856
  33. Gulleroglu K, Fidan K, Hançer VS et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28(5):827-30. doi: 10.1007/s00467-013-2416-9
  34. Кучиева АМ, Козловская НЛ, Демьянова КА, Добросмыслов ИА. Рецидивирующий атипичный гемолитико-уремический синдром, манифестировавший поражением поджелудочной железы. Нефрология и диализ 2013;15(3):236-239
  35. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of the atypical hemolytic uremic syndrome in chidren. Pediatr Nephrol 2016;31(1):15-39. doi: 10.1007/s00467-015-3076-8
  36. Scully M, Goodship T. How I Treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Br J Haematol 2014;164(6):759-766. doi: 10.1111/bjh.12718
  37. Azoulay E, Knoeble P, Garnacho-Montero J et al. Expert Statements on the Standard of Care in Critically Ill Adult Patients with Atypical Hemolytic Uremic Syndrome. Chest 2017;152(2):424-434
  38. Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thrombosis Journal 2016;14(suppl 1):19. doi: 10.1186/s12959-016-0114-0
  39. Cheong HI, Jo SK, Yoon SS et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 2016;31:1516-1528. doi: 10.3346/jkms.2016.31.10.1516
  40. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH 2009;148:37-47
  41. Kato H, Nangaku M, Hataya H et al. Clinical guides for atypical haemolytic uraemic syndrome in Japan. Clin Exp Nephrol 2016;20(4):536-543. doi: 10/1007/s10157-016-1276-6
  42. Go RS, Winters JL, Leug N et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc 2016;91(9):1189-1211. doi: 10.1016/j.mayocp.2016.05.015
  43. Al-Nouri ZL, Reese JA, Terrell DR et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125(4):616-618
  44. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136
  45. Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30(3):347-362. doi: 10.1007/s40620-016-0357-7
  46. El-Husseini A, Hannan S, Awad A et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65(1):127-130
  47. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-867
  48. Zhang B, Xing C, Yu X et al. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 2008;31:479-483
  49. Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-1425
  50. Шевченко ЮЛ, Новик АА, Мельниченко ВЯ. Анемии (руководство по диагностике и лечению). М.: РАЕН, 2012. – 350 с. https://akusher-lib.ru/wp-content/uploads/2019/07/Anemii-rukovodstvo-po-diagnostike-i-lecheniyu.pdf
  51. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome:case-control study. BMJ 2012;19;345:e4565. doi: 10.1136/bmj.e4565
  52. Shah N, Rutherford C, Matevosyan K et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013;163(4):514-9. doi: 10.1111/bjh.12569
  53. Bendapudi PK, Li A, Hamdan A et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol 2015;171(5):836-44. doi: 10.1111/bjh.13658
  54. Hassan S, Westwood JP, Ellis D et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 2015;171(5):830-5. doi: 10.1111/bjh.13654
  55. Coppo P, Schwarzinger M, Buffet M et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010;5(4):e10208
  56. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012;157(4):501-503
  57. Phillips EH, Westwood JP, Brocklebank V et al. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14(1):175-85. doi: 10.1111/jth.13189
  58. Wada H, Matsumoto T, Suzuki K et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018;16:14. doi: 10.1186/s12959-018-0168-2
  59. Lee H, Kang E, Kang HG et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020;35(1):25-40. doi: 10.3904/kjim.2019.388
  60. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014;133(suppl 1):S28-S31
  61. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844-1859
  62. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8(4):554-62
  63. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013;33:508-530. doi: 10.1016/j.semnephrol.2013.08.003
  64. Cataland SR, Holers VM, Geyer S et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014;123:3733-3738
  65. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-1726
  66. Schaefer F, Ardissino G, Ariceta G et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018;94:408-418. doi: 10.1016/j.kint.2018.02.029
  67. Jiang H, Fan MN, Yang M et al. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016;13(12):1209. doi: 10.3390/ijerph13121209
  68. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138
  69. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2015;35(5):421-447. doi: 10.1016/j.nefro.2015.07.005
  70. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 2009;24:1048-1050
  71. Zuber J, Le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7(1):23-35. doi: 10.1038/nrneph.2010.155
  72. Caprioli J, Noris M, Brioschi S et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108(4):1267-1279. doi: 10.1182/blood-2005-10-007252
  73. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Seminars in Dialysis 2012;25(2):214-219. doi: 10.1111/j.1525-139X.2011.01035x
  74. Fox LC, Cohney SJ, Kausman JY et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton) 2018;23(6):507-517. doi: 10.1111/nep.13234
  75. Michael M, Elliott EJ, Craig JC et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53(2):259-72. doi: 10.1053/j.ajkd.2008.07.038
  76. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002;6(4):320-8. doi: 10.1046/j.1526-0968.2002.00390.x
  77. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82(1):27-38. doi: 10.1097/00005792-200301000-00003
  78. Loirat C, Grnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:673-681
  79. Clark WF, Huang SS, Walsh MW et al. Plasmapheresis for the treatment of kidney diseases. Kidney Int 2016;90:974-984. doi: 10.1016/j.kint.2016.06.009
  80. Schwartz J, Padmanabhan A, Aqui N et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149-162. doi: 10.1002/jca.21470
  81. Claes KJ, Massart A, Collard L et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg 2018;73:80-89. doi: 10.1080/17843286.2017.1345185
  82. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998;13(1):16-19
  83. Zuber J, Fakhouri F, Roumenina LT et al.; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-657. doi: 10.1038/nrneph.2012.214
  84. Krishnappa V, Gupta M, Elrifai M et al. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Ther Apher Dial 2018;22(2):178-188. doi: 10.1111/1744-9987.12641
  85. Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol 2020;30(1):35-38. doi: 10.4103/ ijn.IJN_336_18
  86. Sana G, Dragon-Durey MA, Charbit M et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014;29:75-83
  87. Cofiell R, Kukreja A, Bedard K et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Вlood 2015;21;125(21):3253-62. doi: 10.1182/blood-2014-09-600411
  88. Legendre CM, Licht C, Muus PL et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181. doi: 10.1056/NEJMoa1208981
  89. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073. doi: 10.1038/ki.2014.423
  90. Pugh D, O'Sullivan ED, Duthie FA et al. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3(3):CD012862. doi: 10.1002/14651858
  91. Bernuy-Guevara C, Chehade H, Muller YD et al. The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines 2020;8(9):355. doi: 10.3390/biomedicines8090355
  92. Menne J, Delmas Y, Fakhouri F et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long-term observational study. Clin Kidney J 2018;12(2):196-205. doi: 10.1093/ckj/sfy035
  93. Menne J, Delmas Y, Fakhouri F et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology 2019;20:125-137. doi: 10.1186/s12882-019-1314-1
  94. Walle JV, Delmas Y, Ardissino G et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30(1):127-134. doi: 10.1007/s40620-016-0288-3
  95. Ardissino G, Possenti I, Tel F et al. Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015;66:172-173
  96. Olson SR, Lu E, Sulpizio E et al. When to stop Eculizumab in complement-mediated microangiopathies. Am J Nephrol 2018;48:96-107. doi: 10.1159/000492033
  97. Клинические рекомендации. Артериальная гипертензия у взрослых. 2024. https://cr.minzdrav.gov.ru/viev-cr/62_4
  98. Каабак ММ, Молчанова ЕА, Нестеренко ИВ и др. Резолюция Междисциплинарного совета экспертов. Трансплантация почки у пациентов с атипичным гемолитико-уремическим синдромом: клинические и организационно-методические аспекты ведения пациентов. Нефрология 2018;3:8-14. doi: 10.18565/nephrology.2018.3.8-14
  99. Gonzalez Suarez ML, Thongprayoon C, Mao MA et al. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med 2019;8(7):pii:E919. doi: 10.3390/jcm8070919
  100. Siedlecki AM, Isbel N, Vande Walle J et al.; Global aHUS Registry. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 2018;4(3):434-446. doi: 10.1016/j.ekir.2018.11.010
  101. Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013;73(18):2053-66. doi: 10.1007/s40265-013-0147-7
  102. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001;33(1):15-21. doi: 10.1086/320899
  103. Danzinger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009;9(4):258-262. doi: 10.1111/j.1600-6143.2009.02917.x
  104. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика 2017;1(92):51-55
  105. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99. doi: 10.2215/CJN.00050505
  106. Keller K, Daniel C, Schöcklmann H et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006;21:2724-2735. doi: 10.1093/ndt/gfl340
  107. Nava F, Cappelli G, Mori G et al. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant Proc 2014;46:2263-2268. doi: 10.1016/j.transproceed.2014.07.062
  108. Schwimmer J, Nadasdy TA, Spitalnik PF et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003;41:471-479. doi: 10.1053/ajkd.2003.50058
  109. Rolla D, Fontana I, Ravetti JL et al. De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia. J Renal Inj Prev 2015;4(4):135-138. doi: 10.12861/jrip.2015.28
  110. Zuber J, Le Quintrec M, Krid S et al.; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12:3337-3354. doi: 10.1111/j.1600-6143.2012.04252.x
  111. Matar D, Naqvi F, Racusen LC et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98(11):1205-1212. doi: 10.1097/TP.0000000000000200
  112. Cugno M, Gualtierotti R, Possenti I et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-1448
  113. Wehling C, Amon O, Bommer M et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187(2):304-315. doi: 10.1111/cei.12890
  114. Bruel A, Kavanagh D, Noris M et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 2017;12(8):1237-1247. doi: 10.2215/CJN.00280117
  115. Gupta M, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome. A systematic review. Obstetrics&Gynecology 2020;135:46-58. doi: 10.1097/AOG0000000000003554
  116. Grand'Maison S, Lapinsky S. Insights into pregnancy associated and atypical hemolytic uremic syndrome [published correction appears in Obstet Med 2018;11(4):198]. Obstet Med 2018;11(3):137-140. doi: 10.1177/1753495X18780099
  117. Коротчаева ЮВ, Козловская НЛ, Демьянова КА и соавт. Генетические аспекты акушерского гемолитико-уремического синдрома. Клиническая нефрология 2017;1:12-17
  118. Huerta A, Arjona E, Portoles J et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018;93(2):450-459. doi: 10.1016/j.kint.2017.06.022
  119. Козловская НЛ, Коротчаева ЮВ, Шифман ЕМ, Кудлай ДА. Акушерский атипичный гемолитико-уремический синдром: виновата беременность или ее осложнения? Вопросы гинекологии, акушерства и перинатологии 2020;19(4):81-91. doi: 10.20953/1726–1678-2020-4-81-91
  120. Кирсанова ТВ, Виноградова МА, Федорова ТА. Имитаторы тяжелой преэклампсии и HELLP-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология 2016;12:5-14. doi: 10.18565/aig.2016.12.5-14
  121. Padmanabhan A, Connelly-Smith L, Aqui N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019;34(3):171-354. doi: 10.1002/jca.21705
  122. Stefanovic V. The Extended Use of Eculizumab in pregnancy and complement activation⁻associated diseases affecting maternal, fetal and neonatal kidneys - the future is now? J Clin Med 2019;8(3):407. doi: 10.3390/jcm8030407
  123. Burlinson CEG, Sirounis D, Wally KR, Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth 2018;36:96-107. doi: 10.1016/j.ijoa.2018.04.010
  124. 125. Nabhan AF, Allam NE, Hamed Abdel-Aziz Salama M. Routes of administration of antibiotic prophylaxis for preventing infection after caesarean section. Cochrane Database Syst Rev 2016;6:CD011876. doi: 10.1002/14651858.CD011876.pub2
  125. Lionet A, Provôt F, Glowacki F et al. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2009;2(6):458-60. doi: 10.1093/ndtplus/sfp109
  126. Breville G, Zamberg I, Sadallah S et al. Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies. Front Immunol 2021;11:604759. doi: 10.3389/fimmu.2020.604759
  127. Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. doi: 10.5551/jat.RV17026
  128. Liu Y, Thaker H, Wang C et al. Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2022;15(1):10. doi: 10.3390/toxins15010010
  129. Osborne AJ, Breno M, Borsa NG et al. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018;200(7):2464-2478. doi: 10.4049/jimmunol.1701695
  130. Valoti E, Alberti M, Iatropoulos P et al. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. doi: 10.3389/fimmu.2019.00853
  131. Bu F, Maga T, Meyer NC et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25(1):55-64. doi: 10.1681/ASN.2013050453
  132. Bu F, Zhang Y, Wang K et al. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29(12):2809-2819. doi: 10.1681/ASN.2018070759
  133. Acosta-Medina AA, Moyer AM, Go RS et al. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv 2023;7(3):340-350. doi: 10.1182/bloodadvances.2021006416
  134. Chaturvedi S, Dhaliwal N, Hussain S et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-1512
  135. Fakhouri F, Fila M, Hummel A et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021;137:2438-2449
  136. Bouwmeester R, Duinveld C, Wijnsma KL et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep 2022;8:91-102
  137. Piras R, Valoti E, Alberti M et al. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome. Front Immunol 2023;13:1011580. doi: 10.3389/fimmu.2022.1011580
  138. Rondeau E, Scully M, Ariceta G et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2020;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035
  139. Olson SR, Lu E, Sulpizio E et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol 2018;48(2):96-107. doi: 10.1159/000492033
  140. Ávila A, Cao M, Espinosa M et al. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med (Lausanne) 2023:10:1264310. doi: 10.3389/fmed.2023.1264310
  141. Alberti M, Valoti E, Piras R et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013;13:2201-2206. doi:10.1111/ajt.12297
  142. Dowen F, Wood K, Brown AL et al. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017;10(4):490-493. doi: 10.1093/ckj/sfx030
  143. Korzycka J, Pawłowicz-Szlarska E, Masajtis-Zagajewska A, Nowicki M. Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy. Am J Case Rep 2022;28:23:e936565. doi: 10.12659/AJCR.936565
  144. Tang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. Ren Fail 2023;45(1):2231264. doi: 10.1080/0886022X.2023.2231264
  145. Duineveld C, Bouwmeester RN, Wijnsma KL et al. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation. Kidney Int Rep 2023;8(4):715-726. doi: 10.1016/j.ekir.2023.01.016
  146. Barbour T, Scully M, Ariceta G et al. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep 2021;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884
  147. Schmidt T, Göde M, Mahmud M et al. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome. Transplant Direct 2022;8(2):e1289. doi: 10.1097/TXD.0000000000001289
  148. Jehn U, Altuner U, Pavenstädt H, Reuter S. First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient. Transpl Int 2022:35:10846. doi: 10.3389/ti.2022.10846
  149. Fakhouri F, Scully M, Provo F et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 2020;136(19):2103-2117. doi: 10.1182/blood.2020005221
  150. Gäckler A, Schönermarck U, Dobronravov V et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol 2021;22(1):5. doi: 10.1186/s12882-020-02190-0
  151. Kelly RJ, Hochsmann B, Szer J et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032-1039. doi: 10.1056/NEJMoa1502950
  152. Sarno L, Tufano A, Maruotti GM et al. Eculizumab in pregnancy: a narrative overview. J Nephrol 2019;32:17-25. doi: 10.1007/s40620-018-0517-z
  153. Burwick RM, Burwick N, Feinberg BB. Response: maternal and cord C5a in response to eculizumab. Blood 2015;126:279-280. doi: 10.1182/blood-2015-06-642553
  154. Коротчаева ЮВ, Козловская НЛ, Шифман ЕМ, Моисеев СВ. Экулизумаб в лечении атипичного гемолитико-уремического синдрома, связанного с беременностью: ретроспективное исследование у 85 пациенток. Клиническая фармакология и терапия 2023; 32(3):36-43. doi: 10.32756/0869-5490-2023-3-36-43
  155. Servais A, Devillard N, Fremeaux-Bacchi V et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 2016;31(12):2122-2130. doi: 10.1093/ndt/gfw314
  156. Che M, Moran SM, Smith RJ et al. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy. Kidney International 2024;105:960-970. doi: 10.1016/j.kint.2023.12.021
  157. Abe T, Sasaki A, Ueda T et al. Complement-mediated thrombotic microangiopathy secondary to sepsis induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore) 2017;96(6):e6056, doi: 10.1097/MD.0000000000006056
  158. Коротчаева ЮВ, Козловская НЛ, Шифман ЕМ. Акушерский атипичный гемолитико-уремический синдром и сепсис: есть ли связь? Тромбоз, гемостаз и реология 2022;3:62-73. doi: 10.25555/THR.2022.3.1031
  159. Брико НИ, Намазова-Баранова ЛС, Королева ИС и др. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017; 16(1): 51-54
  160. Levi C, Frémeaux-Bacchi V, Zuber J et al. Transplantation. 2017;101(12):2924-2930. doi: 10.1097/TP.0000000000001909
  161. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence.
  162. Glover EK, Smith-Jackson K, Brocklebank V. et al. Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023;107(4):994-1003. doi: 10.1097/TP.0000000000004355
  163. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011;(10):CD003236. doi: 10.1002/14651858.CD003236.pub2
  164. Intiso D, Di Rienzo F, Russo M et al. Rehabilitation strategy in the elderly. J Nephrol 2012;25 Suppl 19:S90-5. doi: 10.5301/jn.5000138
  165. F Fakhouri, N Schwotzer, V Fremeaux-Bacchi. How I diagnose and treat atypical hemolytic uremic syndrome. Blood 2023;141(9):984-995